Gosh, where to start. This is the new A4, except it’s now the new A5. The old A5 (three-door Coupe and four-door Sportback) range is no more, and the new A4 will be almost the same car ...

Meet the all-new Audi A5 Sportback – a model with which Audi is hedging its bets for the future. Combustion engines are most likely destined for the gibbets, but since a question mark still ...

Amid a slew of recent electric vehicle arrivals, Audi has been rejigging its lineup; if you were a fan of the outgoing A4 line, it’s become absorbed by this – the all-new Audi A5 Sportback saloon.

The all-new Audi A5 represents a new chapter for the Ingolstadt-based brand. With a new platform and tech, does the B10-generation A5 sedan have what it takes to grab segment honours? We drive it in ...

Audi is opening the next chapter in its successful history in the mid-size segment with the new A5 family. Thirty years after the first Audi A4, the sharpened design language of the latest generation, ...

Engine is noisy at higher revs (A5) No Avant (wagon) models in Canada Expect higher prices and expensive options Also: All-New Audi A5 Sedan Debuts as A4 Successor Also: The Best Compact Luxury ...

St-Paul de Vance, France - The 2025 Audi A5 (which will undoubtedly be a 2026 when it arrives here next spring) marks an evolution in the range with a significant renewal, not only in terms of ...

Audi’s A5 and S5 are based on Audi’s Premium Platform Combustion platform, with handsome aerodynamic coupe-like rear styling. Both the current generation (B9) and its replacement (B10 ...

If you're familiar with Audi car models, the Audi A5 Avant we're reviewing here might throw you a bit. More specifically, it's name. To cut a long story short, the A5 Avant is an estate car ...

In keeping with Audi’s new naming system that has electric vehicles (EVs) using even numbers and the rest using odd ones, the brand’s long-standing midsize is now known as the A5. The car has also ...

Offers from our trusted partners on this car and its predecessors ...

Positive results from these trials could significantly boost CORT's revenue potential, especially in non-Cushing's applications like cancer and ALS. Corcept's academic alliances enhance its ...